Gallium Ga-68 Gozetotide Patent Expiration
Gallium Ga-68 Gozetotide is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68. It was first introduced by Univ California Los Angeles
Gallium Ga-68 Gozetotide Patents
Given below is the list of patents protecting Gallium Ga-68 Gozetotide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Locametz | US12109277 | Apparatus and method for penetrating and enlarging adjacent tissue layers | Mar 09, 2036 | Novartis |
| Gozellix | US11027031 | Kit for radiolabelling | Jul 28, 2035 | Telix Innovations |
| Illuccix | US11027031 | Kit for radiolabelling | Jul 28, 2035 | Telix |
| Locametz | US11369590 | PSMA binding ligand-linker conjugates and methods for using | Aug 15, 2028 | Novartis |
Gallium Ga-68 Gozetotide's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Gallium Ga-68 Gozetotide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | Jonsson Comprehensive Cancer Center | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |